JPH053855B2 - - Google Patents
Info
- Publication number
- JPH053855B2 JPH053855B2 JP60119710A JP11971085A JPH053855B2 JP H053855 B2 JPH053855 B2 JP H053855B2 JP 60119710 A JP60119710 A JP 60119710A JP 11971085 A JP11971085 A JP 11971085A JP H053855 B2 JPH053855 B2 JP H053855B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cancer
- leukocytes
- tumor
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000265 leukocyte Anatomy 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 21
- 238000000034 method Methods 0.000 description 13
- 210000002865 immune cell Anatomy 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- -1 Cephalose Polymers 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000012051 hydrophobic carrier Substances 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 210000005008 immunosuppressive cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000032832 immune response to tumor cell Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002084 suppressor macrophage Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60119710A JPS61277628A (ja) | 1985-06-04 | 1985-06-04 | 癌治療用白血球刺激材 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60119710A JPS61277628A (ja) | 1985-06-04 | 1985-06-04 | 癌治療用白血球刺激材 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61277628A JPS61277628A (ja) | 1986-12-08 |
| JPH053855B2 true JPH053855B2 (fr) | 1993-01-18 |
Family
ID=14768181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60119710A Granted JPS61277628A (ja) | 1985-06-04 | 1985-06-04 | 癌治療用白血球刺激材 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61277628A (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2635088A (en) * | 1987-12-04 | 1989-06-08 | Du Pont Merck Pharmaceutical Company, The | Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension |
| WO1990009798A1 (fr) * | 1989-02-24 | 1990-09-07 | Immunotherapeutics, Inc. | Cytokines immobilisees |
| US5849282A (en) * | 1990-05-09 | 1998-12-15 | Otsuka Pharmaceutical Co., Ltd. | Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β |
| JP2587711B2 (ja) * | 1990-05-09 | 1997-03-05 | 大塚製薬 株式会社 | 抗腫瘍剤 |
| JPH04170965A (ja) * | 1990-11-01 | 1992-06-18 | Nippon Koutai Kenkyusho:Kk | リンパ球の活性化方法 |
| WO1996022788A1 (fr) * | 1995-01-26 | 1996-08-01 | Biogen, Inc. | COMPLEXES DE LYMPHOTOXINE-α/β ET ANTICORPS DE RECEPTEUR ANTI-LYMPHOTOXINE-BETA UTILES EN TANT QU'AGENTS ANTI-TUMORAUX |
| EP1449540A4 (fr) * | 2001-11-02 | 2007-01-10 | Sekisui Chemical Co Ltd | Substance d'induction de cytokine et instrument d'induction de cytokine |
| US20060275328A1 (en) * | 2003-04-28 | 2006-12-07 | Sekisui Chemical Co., Ltd. | Instrument for inducing cytokine and method of inducing cytokine |
| WO2004096275A1 (fr) * | 2003-04-28 | 2004-11-11 | Sekisui Chemical Co., Ltd. | Instrument d'induction de cytokine et procede d'induction correspondant |
| EP1808191B1 (fr) * | 2004-09-10 | 2014-01-01 | Kaneka Corporation | Methode de prolifération des lymphocytes in vitro |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60120821A (ja) * | 1983-12-05 | 1985-06-28 | Asahi Chem Ind Co Ltd | 悪性腫瘍治療用白血球刺激材および刺激方法 |
-
1985
- 1985-06-04 JP JP60119710A patent/JPS61277628A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60120821A (ja) * | 1983-12-05 | 1985-06-28 | Asahi Chem Ind Co Ltd | 悪性腫瘍治療用白血球刺激材および刺激方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61277628A (ja) | 1986-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102112600B (zh) | 自然杀伤细胞的增殖方法 | |
| JPWO2012099093A1 (ja) | Ｎｋ細胞強化型血液製剤の製造方法 | |
| CN105101978A (zh) | Nk细胞强化型血液制剂的制造方法 | |
| EP0147689B1 (fr) | Méthode d'induction d'immunocytes antitumoraux, procédé de production d'immunocytes antitumoraux et immunocytes antitumoraux produits par le procédé | |
| JPH053855B2 (fr) | ||
| DE69024447T2 (de) | Induzierer einer tumorlysierenden Zelle, Verfahren und Gerät zur Induzierung tumorlysierender Zellen | |
| AU3420689A (en) | Method and means for immuno-stimulating blood treatment with a mitogen | |
| JPS61280432A (ja) | 抗腫瘍免疫細胞誘導方法 | |
| JP2002171966A (ja) | 臍帯血由来活性化リンパ球及び該リンパ球を主成分とする製剤ならびに該製剤の製造方法、該製剤調整用キット。 | |
| JPH0466210B2 (fr) | ||
| JPH0556360B2 (fr) | ||
| JPH0362700B2 (fr) | ||
| JP2639834B2 (ja) | 免疫記憶細胞懸濁液およびその調製方法 | |
| JPS63160578A (ja) | 抗腫瘍キラ−ｔ細胞の誘導方法 | |
| JP3620863B2 (ja) | インターロイキン１の産生誘導方法 | |
| JPS6193122A (ja) | 刺激剤混入のない悪性腫瘍治療用活性化免疫細胞 | |
| JPH0586929B2 (fr) | ||
| JPS6229524A (ja) | 悪性腫瘍治療用刺激剤 | |
| JP2922565B2 (ja) | Ｔリンパ球亜分画の分離材、分離器および分離方法 | |
| JPH0362699B2 (fr) | ||
| Rella et al. | MLC-activation by acute lymphatic leukemia blasts | |
| JP2000212200A (ja) | Ｔリンパ球培養用担体、活性化ｔリンパ球の製造方法、活性化ｔリンパ球製造用キット及び免疫治療剤 | |
| Verma et al. | The kinetics of colony-stimulating activity elaboration from human bone marrow cells by immunoadjuvants: Interactions between light density adherent and nonadherent cells in vitro | |
| JP2834514B2 (ja) | 血液細胞処理剤 | |
| JPWO2006101205A1 (ja) | Ｔ細胞の活性化方法及び活性化ｔ細胞製造用キット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |